TY  - JOUR
AU  - Dorman, Klara
AU  - Auernhammer, Christoph J
AU  - Spitzweg, Christine
AU  - Schmidmaier, Ralf
AU  - Nölting, Svenja
AU  - Kroiss, Matthias
AU  - Reincke, Martin
AU  - Schulz, Christian
AU  - Angele, Martin
AU  - Werner, Jens
AU  - Schmid-Tannwald, Christine
AU  - Rauch, Josefine
AU  - Zacherl, Mathias
AU  - Knösel, Thomas
AU  - Kumbrink, Jörg
AU  - Jung, Andreas
AU  - Klauschen, Frederick
AU  - Tufman, Amanda
AU  - Zhang, Danmei
AU  - Weiss, Lena
AU  - Böck, Stefan
AU  - von Bergwelt-Baildon, Michael
AU  - Heinemann, Volker
AU  - Westphalen, C. Benedikt
AU  - Heinrich, Kathrin
TI  - Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
JO  - Targeted oncology
VL  - 20
IS  - 4
SN  - 1776-2596
CY  - Paris
PB  - Springer Verlag France S.A.R.L.
M1  - DKFZ-2025-01329
SP  - 715-724
PY  - 2025
N1  - 2025 Jul;20(4):715-724
AB  - Comprehensive genomic profiling (CGP) has become more generally accessible to patients with rare cancer, but data on the results and benefits are limited.Our objective was to gain a real-world understanding of the molecular landscape and targeted treatment options in neuroendocrine tumors, neuroendocrine carcinomas, adrenocortical carcinomas, pheochromocytomas, and carcinoids.In this retrospective cohort study, we analyzed CGP results and clinical data from patients with neuroendocrine tumors, neuroendocrine carcinomas, adrenocortical carcinomas, pheochromocytomas, and carcinoids who were discussed in the CCCMunichLMU Molecular Tumor Board (MTB) between May 2017 and April 2023.In total, 104 patients with endocrine and neuroendocrine neoplasms were discussed in the MTB. CGP was technically successful in 99 patients. The most commonly mutated genes were TP53 (29.3
LB  - PUB:(DE-HGF)16
C6  - pmid:40587033
DO  - DOI:10.1007/s11523-025-01152-6
UR  - https://inrepo02.dkfz.de/record/302789
ER  -